Bausch + Lomb says it is advancing development of an oral candidate for dry age-related macular degeneration (AMD) following a “constructive” meeting with the U.S. Food and Drug Administration (FDA). The company is developing BL1243 (tonabersat) as a potential treatment for patients with earlier-stage dry AMD, where therapeutic options are described as limited.
Bausch + Lomb indicates that the discussion with the FDA supports progress toward future clinical evaluation and that a development program is expected to begin in 2027. The reporting available here focuses on the regulatory engagement and planned next steps, rather than providing detailed results from prior studies or specific trial designs.
Across the two outlets, the central points align: Bausch + Lomb is pursuing an oral therapy for dry AMD, the candidate is BL1243 (tonabersat), and the FDA meeting is characterized as constructive. Differences are limited because the Seeking Alpha excerpt provided includes no additional detail beyond the announcement’s theme.
